TW202128690A - 吡唑并雜芳基類衍生物、其製備方法及其在醫藥上的應用 - Google Patents

吡唑并雜芳基類衍生物、其製備方法及其在醫藥上的應用 Download PDF

Info

Publication number
TW202128690A
TW202128690A TW109140787A TW109140787A TW202128690A TW 202128690 A TW202128690 A TW 202128690A TW 109140787 A TW109140787 A TW 109140787A TW 109140787 A TW109140787 A TW 109140787A TW 202128690 A TW202128690 A TW 202128690A
Authority
TW
Taiwan
Prior art keywords
group
general formula
cycloalkyl
aryl
heteroaryl
Prior art date
Application number
TW109140787A
Other languages
English (en)
Chinese (zh)
Inventor
李心
董懷德
白東棟
賀峰
陶維康
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
大陸商上海恆瑞醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司, 大陸商上海恆瑞醫藥有限公司 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW202128690A publication Critical patent/TW202128690A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW109140787A 2019-11-21 2020-11-20 吡唑并雜芳基類衍生物、其製備方法及其在醫藥上的應用 TW202128690A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201911147956 2019-11-21
CN201911147956.3 2019-11-21
CN202010837381.4 2020-08-19
CN202010837381 2020-08-19

Publications (1)

Publication Number Publication Date
TW202128690A true TW202128690A (zh) 2021-08-01

Family

ID=75981069

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109140787A TW202128690A (zh) 2019-11-21 2020-11-20 吡唑并雜芳基類衍生物、其製備方法及其在醫藥上的應用

Country Status (11)

Country Link
US (1) US12559488B2 (https=)
EP (1) EP4063363A4 (https=)
JP (1) JP7781059B2 (https=)
KR (1) KR20220103987A (https=)
CN (5) CN120004887A (https=)
AU (1) AU2020386587A1 (https=)
BR (1) BR112022008000A2 (https=)
CA (1) CA3159376A1 (https=)
MX (1) MX2022005985A (https=)
TW (1) TW202128690A (https=)
WO (1) WO2021098811A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112142744A (zh) 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
TW202220993A (zh) * 2020-08-07 2022-06-01 香港商德琪研發有限公司 Atr抑制劑及其用途
WO2022135560A1 (en) * 2020-12-25 2022-06-30 Impact Therapeutics (Shanghai) , Inc Substituted imidazo[1,5-b]pyridazine compounds as kinase inhibitors and use thereof
KR20240012471A (ko) 2021-05-21 2024-01-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 피라졸로헤테로아릴계 유도체의 약학적으로 허용 가능한 염 및 이의 결정형
WO2023109883A1 (zh) * 2021-12-15 2023-06-22 上海翊石医药科技有限公司 一类芳杂环取代的化合物及其制备方法和用途
WO2024109727A1 (zh) * 2022-11-21 2024-05-30 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的可药用盐的结晶形式
CN119143753B (zh) * 2023-06-14 2026-01-02 石药集团中奇制药技术(石家庄)有限公司 一种杂环类抗肿瘤化合物的盐及其晶型

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
US20110053923A1 (en) * 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
CA2819373A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
ME03336B (me) 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
US20190000850A1 (en) 2015-02-09 2019-01-03 The Regents Of The University Of California Combination cancer therapy
WO2017118734A1 (en) 2016-01-08 2017-07-13 The Institute Of Cancer Research: Royal Cancer Hospital Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer
CA3011189C (en) 2016-01-14 2024-02-20 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
US11730734B2 (en) 2016-09-12 2023-08-22 University Of Florida Research Foundation, Incorporated Use of ATR and Chk1 inhibitor compounds
WO2018153970A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine
EP3679041B1 (en) 2017-09-08 2022-07-06 Newave Pharmaceutical Inc. Substituted pyrrolopyridines as atr inhibitors
CN112654396B (zh) * 2018-09-07 2025-07-01 默克专利股份公司 5-吗啉-4-基-吡唑并[4,3-b]吡啶衍生物
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators

Also Published As

Publication number Publication date
JP2023502458A (ja) 2023-01-24
CN114423760A (zh) 2022-04-29
CN120004886A (zh) 2025-05-16
WO2021098811A1 (zh) 2021-05-27
KR20220103987A (ko) 2022-07-25
EP4063363A1 (en) 2022-09-28
AU2020386587A1 (en) 2022-06-02
BR112022008000A2 (pt) 2022-07-12
CN120004872A (zh) 2025-05-16
EP4063363A4 (en) 2023-11-29
JP7781059B2 (ja) 2025-12-05
CN120004888A (zh) 2025-05-16
CA3159376A1 (en) 2021-05-27
US20230018728A1 (en) 2023-01-19
CN120004887A (zh) 2025-05-16
MX2022005985A (es) 2022-06-17
US12559488B2 (en) 2026-02-24
CN114423760B (zh) 2024-12-27

Similar Documents

Publication Publication Date Title
TW202128690A (zh) 吡唑并雜芳基類衍生物、其製備方法及其在醫藥上的應用
TW202322819A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
TW202214608A (zh) 稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用
WO2023072297A1 (zh) 含氮的四环化合物、其制备方法及其在医药上的应用
WO2022247816A1 (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
CN115594695A (zh) 大环类化合物、其制备方法及其在医药上的应用
TW201835079A (zh) 6-吡唑-[1,2,4]三唑並[4,3-α]吡啶-3-醯胺類衍生物、其製備方法及其在醫藥上的應用
TW202128686A (zh) 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
WO2022166810A1 (zh) 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
TW202136269A (zh) 稠合二環類衍生物、其製備方法及其在醫藥上的應用
TW202128660A (zh) 稠合吡啶環衍生物、其製備方法及其在醫藥上的應用
CN115867552B (zh) 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
CN115836077B (zh) 氧杂氮杂螺环类衍生物、其制备方法及其在医药上的应用
CN113004303A (zh) 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用
HK40070277A (en) Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof
HK40070277B (zh) 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN113135942B (zh) 稠合嘧啶类衍生物、其制备方法及其在医药上的应用
TW202140474A (zh) 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
CN115835863B (zh) 氧杂氮杂双环类衍生物、其制备方法及其在医药上的应用
TW202128707A (zh) 稠合四環類衍生物、其製備方法及其在醫藥上的應用
TW202317572A (zh) 雜環大環化合物及其醫藥用途
CN120098001A (zh) 作为细胞周期蛋白依赖性激酶抑制剂的噻吩类化合物及其制备方法和医药用途
WO2025113705A1 (zh) N-取代酰胺类衍生物抑制剂、其制备方法和应用
TW202345852A (zh) 稠雜環類化合物、其製備方法及其在醫藥上的應用